David Pierce - Boston Scientific President
BSX Stock | USD 72.93 0.08 0.11% |
President
Mr. David A. Pierce is Executive Vice President and President MedSurg of the Company. In this role, he has direct responsibility for the Urology and Pelvic Health and Endoscopy businesses, Canada and Latin America regions, and Corporationrationrate Marketing and Market Access. Prior to his current role, Mr. Pierce served as the Senior Vice President and President, Urology and Pelvic Health since July 2016. In that role, he developed and executed strategies to bring to market industryleading solutions for treating patients with urological, urogynecological and gynecological diseases. Previously, Mr. Pierce served as senior vice president and president, Endoscopy since 2011, and vice president, Marketing for Endoscopy as well as group marketing director in the Endoscopy business. He joined Boston Scientific in 1991 as a territory manager before assuming managementlevel positions of increasing responsibility. Prior to joining Boston Scientific, Mr. Pierce also served as senior sales representative for Airborne Express and as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University. since 2020.
Age | 57 |
Tenure | 4 years |
Professional Marks | MBA |
Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
Phone | 508 683 4000 |
Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0925 %, implying that it generated $0.0925 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.14 in 2024, whereas Return On Equity is likely to drop 0.06 in 2024. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 30.1 B in 2024, whereas Total Current Assets are likely to drop slightly above 3.3 B in 2024.Similar Executives
Found 1 records | PRESIDENT Age | ||
Ted McNulty | MidCap Financial Investment | N/A |
Management Performance
Return On Equity | 0.0925 | ||||
Return On Asset | 0.0454 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Ludwig, Lead Independent Director | ||
Donna James, Independent Director | ||
Stephen MacMillan, Independent Director | ||
Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
Emily Woodworth, Global VP | ||
Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
Ellen Zane, Independent Director | ||
Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
Nelda Connors, Independent Director | ||
Wendy Carruthers, Executive Vice President - Human Resources | ||
Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
Catherine Jennings, VP Interventions | ||
John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
Edward Mackey, Executive Vice President - Global Operations | ||
Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
Charles Dockendorff, Independent Director | ||
Mary Moynihan, Senior Officer | ||
John Sununu, Independent Director | ||
Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
Yoshiaki Fujimori, Independent Director | ||
David Wichmann, Independent Director | ||
David Roux, Independent Director | ||
Susan Lisa, VP, Investor Relations | ||
Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | ||||
Return On Asset | 0.0454 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.18 % | ||||
Current Valuation | 116.02 B | ||||
Shares Outstanding | 1.47 B | ||||
Shares Owned By Insiders | 0.19 % | ||||
Shares Owned By Institutions | 94.51 % | ||||
Number Of Shares Shorted | 13.16 M | ||||
Price To Earning | 107.05 X |
Pair Trading with Boston Scientific
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boston Scientific position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boston Scientific will appreciate offsetting losses from the drop in the long position's value.Moving against Boston Stock
0.79 | INNV | InnovAge Holding Corp Financial Report 14th of May 2024 | PairCorr |
0.78 | INMD | InMode Financial Report 7th of May 2024 | PairCorr |
0.74 | PEN | Penumbra Financial Report 7th of May 2024 | PairCorr |
0.67 | NARI | Inari MedicalInc | PairCorr |
0.65 | CVS | CVS Health Corp | PairCorr |
The ability to find closely correlated positions to Boston Scientific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boston Scientific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boston Scientific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boston Scientific Corp to buy it.
The correlation of Boston Scientific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boston Scientific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boston Scientific Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boston Scientific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Boston Stock analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.579 | Earnings Share 1.19 | Revenue Per Share 10.065 | Quarterly Revenue Growth 0.138 | Return On Assets 0.0454 |
The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.